Development Programs

Infectious Disease

Preclinical
Phase 1
Phase 2
Phase 3
Sci-B-Vac®

VLP

Approved (Licensed in 10 Countries)

100%

Phase 3 (US, EU, CAN)

87%
VBI-2601

VLP

Preclinical

25%
VBI-1501

eVLP

Phase 1 Complete

52%
VBI-2501

eVLP

Preclinical

15%

Immuno-Oncology

Preclinical
Phase 1
Phase 2
Phase 3
VBI-1901

eVLP

Phase 1/2a

40%
VBI-1901

eVLP

Preclinical

25%